These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 28075132)

  • 1. Discovery of Imidazo[1,2-a]pyridine Ethers and Squaramides as Selective and Potent Inhibitors of Mycobacterial Adenosine Triphosphate (ATP) Synthesis.
    Tantry SJ; Markad SD; Shinde V; Bhat J; Balakrishnan G; Gupta AK; Ambady A; Raichurkar A; Kedari C; Sharma S; Mudugal NV; Narayan A; Naveen Kumar CN; Nanduri R; Bharath S; Reddy J; Panduga V; Prabhakar KR; Kandaswamy K; Saralaya R; Kaur P; Dinesh N; Guptha S; Rich K; Murray D; Plant H; Preston M; Ashton H; Plant D; Walsh J; Alcock P; Naylor K; Collier M; Whiteaker J; McLaughlin RE; Mallya M; Panda M; Rudrapatna S; Ramachandran V; Shandil R; Sambandamurthy VK; Mdluli K; Cooper CB; Rubin H; Yano T; Iyer P; Narayanan S; Kavanagh S; Mukherjee K; Balasubramanian V; Hosagrahara VP; Solapure S; Ravishankar S; Hameed P S
    J Med Chem; 2017 Feb; 60(4):1379-1399. PubMed ID: 28075132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis.
    Singh S; Roy KK; Khan SR; Kashyap VK; Sharma A; Jaiswal S; Sharma SK; Krishnan MY; Chaturvedi V; Lal J; Sinha S; Dasgupta A; Srivastava R; Saxena AK
    Bioorg Med Chem; 2015 Feb; 23(4):742-52. PubMed ID: 25614114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and structure activity relationship of imidazo[1,2-a]pyridine-8-carboxamides as a novel antimycobacterial lead series.
    Ramachandran S; Panda M; Mukherjee K; Choudhury NR; Tantry SJ; Kedari CK; Ramachandran V; Sharma S; Ramya VK; Guptha S; Sambandamurthy VK
    Bioorg Med Chem Lett; 2013 Sep; 23(17):4996-5001. PubMed ID: 23867166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of mycobacterial ATP synthase inhibition by squaramides and second generation diarylquinolines.
    Courbon GM; Palme PR; Mann L; Richter A; Imming P; Rubinstein JL
    EMBO J; 2023 Aug; 42(15):e113687. PubMed ID: 37377118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Halting ionic shuttle to disrupt the synthetic machinery-Structural and molecular insights into the inhibitory roles of Bedaquiline towards Mycobacterium tuberculosis ATP synthase in the treatment of tuberculosis.
    Salifu EY; Agoni C; Olotu FA; Dokurugu YM; Soliman MES
    J Cell Biochem; 2019 Sep; 120(9):16108-16119. PubMed ID: 31125144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small organic molecules targeting the energy metabolism of Mycobacterium tuberculosis.
    Urban M; Šlachtová V; Brulíková L
    Eur J Med Chem; 2021 Feb; 212():113139. PubMed ID: 33422979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unique structural and mechanistic properties of mycobacterial F-ATP synthases: Implications for drug design.
    Kamariah N; Ragunathan P; Shin J; Saw WG; Wong CF; Dick T; Grüber G
    Prog Biophys Mol Biol; 2020 May; 152():64-73. PubMed ID: 31743686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phenotypic Based Target Screening Approach Delivers New Antitubercular CTP Synthetase Inhibitors.
    Esposito M; Szadocka S; Degiacomi G; Orena BS; Mori G; Piano V; Boldrin F; Zemanová J; Huszár S; Barros D; Ekins S; Lelièvre J; Manganelli R; Mattevi A; Pasca MR; Riccardi G; Ballell L; Mikušová K; Chiarelli LR
    ACS Infect Dis; 2017 Jun; 3(6):428-437. PubMed ID: 28475832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular docking-based interaction studies on imidazo[1,2-a] pyridine ethers and squaramides as anti-tubercular agents.
    Ahmed S; Prabahar AE; Saxena AK
    SAR QSAR Environ Res; 2023; 34(6):435-457. PubMed ID: 37365919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arylvinylpiperazine Amides, a New Class of Potent Inhibitors Targeting QcrB of Mycobacterium tuberculosis.
    Foo CS; Lupien A; Kienle M; Vocat A; Benjak A; Sommer R; Lamprecht DA; Steyn AJC; Pethe K; Piton J; Altmann KH; Cole ST
    mBio; 2018 Oct; 9(5):. PubMed ID: 30301850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanding the squaramide library as mycobacterial ATP synthase inhibitors: Innovative synthetic pathway and biological evaluation.
    Chasák J; Oorts L; Dak M; Šlachtová V; Bazgier V; Berka K; De Vooght L; Smiejkowska N; Calster KV; Van Moll L; Cappoen D; Cos P; Brulíková L
    Bioorg Med Chem; 2023 Nov; 95():117504. PubMed ID: 37871508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An update on ATP synthase inhibitors: A unique target for drug development in M. tuberculosis.
    Kelam LM; Wani MA; Dhaked DK
    Prog Biophys Mol Biol; 2023; 180-181():87-104. PubMed ID: 37105260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bactericidal activity of an imidazo[1, 2-a]pyridine using a mouse M. tuberculosis infection model.
    Cheng Y; Moraski GC; Cramer J; Miller MJ; Schorey JS
    PLoS One; 2014; 9(1):e87483. PubMed ID: 24498115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis.
    Worley MV; Estrada SJ
    Pharmacotherapy; 2014 Nov; 34(11):1187-97. PubMed ID: 25203970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arrival of Imidazo[2,1-b]thiazole-5-carboxamides: Potent Anti-tuberculosis Agents That Target QcrB.
    Moraski GC; Seeger N; Miller PA; Oliver AG; Boshoff HI; Cho S; Mulugeta S; Anderson JR; Franzblau SG; Miller MJ
    ACS Infect Dis; 2016 Jun; 2(6):393-8. PubMed ID: 27627627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imidazopyridine Compounds Inhibit Mycobacterial Growth by Depleting ATP Levels.
    O'Malley T; Alling T; Early JV; Wescott HA; Kumar A; Moraski GC; Miller MJ; Masquelin T; Hipskind PA; Parish T
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29632008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure of mycobacterial ATP synthase bound to the tuberculosis drug bedaquiline.
    Guo H; Courbon GM; Bueler SA; Mai J; Liu J; Rubinstein JL
    Nature; 2021 Jan; 589(7840):143-147. PubMed ID: 33299175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A tale of two inhibitors: diarylquinolines and squaramides.
    Chen J; Ekiert DC
    EMBO J; 2023 Aug; 42(15):e114912. PubMed ID: 37435707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isoniazid Bactericidal Activity Involves Electron Transport Chain Perturbation.
    Zeng S; Soetaert K; Ravon F; Vandeput M; Bald D; Kauffmann JM; Mathys V; Wattiez R; Fontaine V
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30642937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis.
    Andries K; Verhasselt P; Guillemont J; Göhlmann HW; Neefs JM; Winkler H; Van Gestel J; Timmerman P; Zhu M; Lee E; Williams P; de Chaffoy D; Huitric E; Hoffner S; Cambau E; Truffot-Pernot C; Lounis N; Jarlier V
    Science; 2005 Jan; 307(5707):223-7. PubMed ID: 15591164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.